A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy. | LitMetric

AI Article Synopsis

  • Progressive multifocal leukoencephalopathy (PML) is a serious viral disease that can occur in multiple sclerosis (MS) patients, especially those treated with the drug natalizumab, highlighting the importance of early detection to adjust treatment plans.
  • A case study of a 57-year-old woman with relapsing-remitting MS revealed that she developed PML linked to natalizumab, exhibiting behavioral changes and brain abnormalities over time.
  • The findings underscore the need for awareness of unique cognitive deficits in MS patients to facilitate quicker diagnosis of PML and address treatment-related complications.

Article Abstract

Background: Progressive multifocal leukoencephalopathy (PML) is a viral disease characterized by progressive damage or inflammation of the cerebral white matter that can be encountered in patients with multiple sclerosis (MS). There are cases of PML caused by pharmacological agents including natalizumab. Therefore, in patients treated with this drug, early identification of PML allows changes in the treatment plan, reducing the risks of morbidity and mortality.

Case Presentation: We reported the case of a 57-year-old female diagnosed with relapsing-remitting MS, who presented with PML related to natalizumab. The patient presented with change in behavioral, radiological abnormalities in the left parieto-temporal lobes. We described the longitudinal course of PML, from the diagnosis until the patient's death, documenting the progressive deterioration of her cognitive functioning, supported by changes on sequential brain scans and neurophysiological data.

Conclusion: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025511PMC
http://dx.doi.org/10.3390/medicina58040551DOI Listing

Publication Analysis

Top Keywords

progressive multifocal
8
multifocal leukoencephalopathy
8
pml
6
neuropsychological disability
4
disability case
4
case natalizumab-related
4
progressive
4
natalizumab-related progressive
4
leukoencephalopathy background
4
background progressive
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!